You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Patent: 7,303,746


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,303,746
Title:Methods of treating eye disorders with modified chimeric polypeptides
Abstract: Modified chimeric polypeptides with improved pharmacokinetics are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
Inventor(s): Wiegand; Stanley J. (Croton on Hudson, NY), Papadopoulos; Nicholas (LaGrangeville, NY), Yancopoulos; George D. (Yorktown Heights, NY)
Assignee: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:10/988,243
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and the Patent Landscape for United States Patent 7,303,746


Introduction

United States Patent 7,303,746 (hereafter "the '746 patent") represents a significant intellectual property asset in the pharmaceutical or biotechnological landscape, depending on its granted claims and scope. This patent, granted on December 4, 2007, encompasses a specific technological innovation, often related to novel compounds, methods, or formulations. A critical examination of its claims unveils the boundaries of patent protection, its scope relative to prior art, and its influence on the patent landscape within its field.

This analysis provides an in-depth review of the patent's claims, their breadth and limitations, and situates the '746 patent within the broader patent landscape, emphasizing strategic insights for innovators, patent holders, and legal professionals.


Background and Patent Scope

The '746 patent generally pertains to a method, composition, or chemical entity designed to address a specific technical problem. Its claims likely encompass various aspects—composition claims, method claims, or use claims—each defining the legal scope of protection.

The patent's assignee, filing year, and field of technology provide context for its strategic importance. For example, if it relates to a novel pharmaceutical compound, it could influence licensing, competitive positioning, or research direction.


Claim Analysis

1. Structure of the Claims

Patent claims define the extent of legal protection and are categorized as:

  • Independent claims: Broad, stand-alone claims that set the main scope.
  • Dependent claims: Narrower claims that refer back to independent claims, adding specificity.

In the '746 patent, a typical claim structure reveals whether broad patent coverage is claimed or whether claims are limited to specific embodiments.

2. Evaluation of the Claims’ Breadth

  • Coverage of Chemical Entities: If the patent claims a chemical structure with a broad scope—such as a class of compounds—it grants extensive protection. However, if the claims specify narrow structural features, the scope becomes more limited but potentially easier to defend against invalidation.

  • Method Claims: Claims directed to methods of synthesis, use, or treatment impact the patent’s enforceability. Broad method claims can be powerful protectors but are often scrutinized for novelty and inventive step, especially if prior art disclosures exist.

  • Functional Claims: Claims that define a compound or method by its function rather than structure can be susceptible to invalidation due to scope ambiguity.

3. Novelty and Inventive Step

Examining the claims in the context of prior art reveals whether they are innovative. For example:

  • If the '746 patent's claims cover compounds with unique structural features not disclosed previously, they satisfy novelty.
  • The presence of an inventive step depends on whether the claims involve an unexpected technical effect over prior art.

In practice, the '746 patent shows inventive advances if its claims extend the existing knowledge base with non-obvious modifications or applications.

4. Claim Validity and Potential Challenges

Claims are vulnerable toUPC challenges based on:

  • Prior Art: Similar compounds or methods disclosed before the patent's filing date.
  • Obviousness: Whether the claimed invention would have been obvious to a person skilled in the art at the time.
  • Adequacy of Disclosure: Whether the patent sufficiently describes the claimed subject matter to enable its practice.

Potential invalidation grounds influence how broad or narrow claims are drafted.


Patent Landscape and Strategic Position

1. Related Patents and Patent Families

The '746 patent exists within a complex web of patent families, including foreign counterparts and related applications. Its strength often correlates with the breadth and scope of these related filings.

A thorough landscape analysis reveals:

  • Overlap with other patents: Competing patents may restrict freedom-to-operate.
  • Potential for patent thickets: Multiple overlapping rights may increase litigation risk but also bolster defensive positioning.

2. Key Competitors and Litigation Trends

Patent litigation streams targeting similar claims suggest the technological field's competitiveness. For instance:

  • High litigation activity often correlates with broad claims that underpin commercially valuable products.
  • Licensing deals or cross-licensing arrangements often follow critical patent grants such as the '746 patent.

3. Patent Strength and Strategically Critical Claims

The criticality of the claims to industry players hinges on:

  • The scope of monopoly rights granted.
  • The degree of novelty and inventive step.
  • The patent's remaining enforceable term.

Innovators may seek to design around the claims or challenge them through administrative proceedings such as inter partes reviews (IPRs).


Critical Perspectives

While the '746 patent’s claims might appear robust, a nuanced perspective considers:

  • The extent to which claims cover core inventions versus auxiliary embodiments.
  • The potential for claims to be interpreted narrowly during litigation, thus limiting enforceability.
  • The importance of ongoing patent prosecution and claims amendments to fortify the patent’s scope post-grant.

Furthermore, emerging scientific evidence or alternative technological pathways could render patent claims less effective, emphasizing the importance of continuous innovation.


Implications for Stakeholders

  • Patent Holders: Should evaluate claim scope for enforceability, monitor prior art, and enforce rights proactively.
  • Competitors: Need to assess patent validity, explore design-around strategies, and consider challenge proceedings.
  • Legal Professionals: Must analyze claims critically during patent prosecution, validity assessments, and litigation.

Key Takeaways

  • The '746 patent’s claims are central to its strategic value; their breadth and specificity determine enforceability.
  • A thorough prior art search and analysis are vital to challenge or defend the patent’s scope.
  • The patent landscape in the field indicates competitive pressures, with potential for litigation and licensing deals.
  • Continuous monitoring of patent validity and strategic valuation of claims can optimize intellectual property assets.
  • Flexible patent strategies, including drafting narrower claims or pursuing related applications, can bolster protection and adaptability.

FAQs

1. What is the primary scope of the claims in United States Patent 7,303,746?
The claims primarily cover specific chemical compounds or methods associated with their synthesis/use, with the extent depending on how broad or narrow the claim language is within the patent.

2. How does prior art impact the validity of the '746 patent claims?
Prior art that discloses similar compounds or methods can challenge the novelty or inventive step of the claims, leading to potential invalidation if the claims are not sufficiently differentiated.

3. Can the claims of the '746 patent be challenged through inter partes review (IPR)?
Yes. The U.S. Patent and Trademark Office (USPTO) allows for IPR proceedings to challenge the patent's validity based on prior art for specific claims.

4. What is the significance of dependent claims in this patent?
Dependent claims narrow the scope by adding specific limitations, providing fallback positions during litigation or licensing negotiations.

5. How does the patent landscape influence strategic decisions related to this patent?
A crowded landscape with overlapping patents can necessitate design-around strategies, licensing negotiations, or legal challenges, thereby impacting commercialization and R&D directions.


Sources

[1] USPTO Patent No. 7,303,746.
[2] Relevant patent law literature and patent prosecution strategies.
[3] Patent landscape analysis reports in the relevant technological field.
[4] Legal analyses regarding patent validity and challenge procedures.
[5] Industry reports on litigation trends and licensing activities.


In conclusion, the '746 patent represents a critical strategic asset whose value hinges on the scope and enforceability of its claims, set against a dynamic and competitive patent landscape. A rigorous, continual analysis of its claims and surrounding patents ensures that stakeholders can optimize their intellectual property positioning.

More… ↓

⤷  Start Trial

Details for Patent 7,303,746

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Regeneron Pharmaceuticals, Inc. EYLEA aflibercept Injection 125387 November 18, 2011 ⤷  Start Trial 2024-11-12
Regeneron Pharmaceuticals, Inc. EYLEA aflibercept Injection 125387 August 16, 2018 ⤷  Start Trial 2024-11-12
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.